Clinical Research Directory
Browse clinical research sites, groups, and studies.
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML
Sponsor: Affiliated Hospital to Academy of Military Medical Sciences
Summary
The aim of this Phase Ⅰ/Ⅱ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
Official title: Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML: a Phase Ⅰ/Ⅱ Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2013-06
Completion Date
2024-12-30
Last Updated
2024-07-01
Healthy Volunteers
No
Conditions
Interventions
Adenovirus-transfected DC + CIK
Adenovirus-transfected autologous DC vaccine plus CIK cells
Locations (1)
Department of Hematopoietic Stem Cell Transplantation
Beijing, China